GenEdit
CA - BrisbaneBiotechnology
Focus: GenEdit develops nonviral CRISPR-delivery systems for gene therapy applications, positioning itself in the cutting-edge cell and gene therapy space. The company is at Series B stage, indicating early-stage development with meaningful capital behind its platform.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
SERIES B
Open Jobs
4+1 this month
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
Should You Work at GenEdit?
AI assessmentGenEdit is an early-stage deep-tech bet in CRISPR delivery suitable for scientists seeking equity upside and platform building, but with significant execution risk and minimal public validation of technical progress.
Why Work Here
- Ground-floor opportunity in CRISPR gene therapy with proprietary nonviral delivery—a critical bottleneck solving challenge in the field
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GenEdit
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.